Session Title: Vascular Diseases and Diabetic Retinopathy IV
Session Date/Time: Sunday 20/09/2015 | 09:00-10:30
Paper Time: 09:40
First Author: : K.Eibenberger AUSTRIA
Co Author(s): : S. Rezar D. Schmidl R. Told U. SchmidtErfurth L. Schmetterer S. Sacu
PURPOSE:To investigate the effects of intravitreal Dexamethasone treatment (Ozurdex®) on retrobulbar blood velocity and oxygen saturation in retinal vessels in patients with macular edema (ME) due to either central- (CRVO) or branch retinal vein occlusion (BRVO) after 6 months.
In this prospective non-randomized clinical trial, 40 eyes of 39 patients with ME due to RVO (25 BRVO and 15 CRVO), were recruited at the Department of Ophthalmology, Vienna General Hospital.
The patients were followed-up monthly until six months after initial visits and one week following each Ozurdex® treatment. At every visit a complete ophthalmologic clinical examination, including ETDRS visual acuity (VA), indirect biomicroscopy and SD-OCT was performed. Retrobulbar blood velocity using color doppler imaging and oxygen saturation using a Retinal Vessel Analyzer were compared.
Mean VA at baseline in patients (m:f=25:15, mean age:69.5±12.1years) was 64±15 letters and increased significantly to 71±16 letters ETDRS at 6 months (p<0,05). Mean CRT was 533±153m at baseline and decreased to 303±77m after 6months (p<0,05). Retinal artery diameters (baseline: 102±2 month 6: 101±19; p=0,79) and oxygen saturation (BSL: 96±4 vs. 6months: 94±3; p=0,361) did not change significantly. In veins the vessel diameter (BSL: 152±21, 6mo: 138±17; p=0,078) and the retinal oxygenation (bsl: 78±9, 6mo: 74±9; p=0,091) showed a decrease over time.
Intravitreal dexamethasone seems to be effective in the treatment of ME secondary to RVO with regard to vision and macular thickness. Furthermore, our results show that intravitreal Dexamethason may have a vasoconstrictive effect on retinal veins in eyes with ME secondary to RVO.